文献速递泌尿生殖腹部MRUS

采用PI-RADS第2版与Likert评分系统对前列腺MRI后癌症检出率的审核

Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems.
PubMed 文献 · Clin Radiol · 2022-05-12

纳入326例疑似前列腺癌接受前列腺MRI的连续男性,记录按PI-RADS与Likert评估分类的活检率及所有癌和ISUP GG≥2癌的组织学检出率;92%的MRI阴性者在MDT审核后避免立即活检,两评分系统对MRI阳性后临床显著癌检出表现等效,不一致似乎主要限于PI-RADS 4类。

要点

  • PI-RADS与Likert评分的一致率为87%,在MRI阴性(99%)与5分(96%)时一致性高。
  • PI-RADS 4组不一致性高,32%的PI-RADS 4类被上调为Likert 5。
  • MRI阴性者在MDT审核后92%避免立即活检。

核心结论

  • 大多数前列腺MRI阴性的男性在MDT审核后可避免立即活检。
  • PI-RADS与Likert评分系统在MRI阳性后临床显著癌检出方面的表现等效。
  • 两系统的不一致似乎主要限于PI-RADS 4类。

研究设计与样本

  • 对更新后的MRI导向前列腺癌诊断服务进行诊断检出率审核,比较PI-RADS第2版与Likert评分的结果。
  • 纳入326例疑似癌症并接受前列腺MRI的连续男性,其中91%未接受过活检。
  • 326例中177例(54%)接受了经直肠(n=119)或经会阴(n=58)超声引导下活检。
  • 在323/326份检查中进行了前瞻性配对的PI-RADS与Likert评分。

诊断标准与关键数值

  • 所有癌与ISUP GG≥2癌的检出率随怀疑评分升高而升高。
  • PI-RADS与Likert评分的总体一致率为87%,MRI阴性时一致率为99%,5分时一致率为96%。
  • PI-RADS 4组不一致性高,32%的PI-RADS 4类被上调为Likert 5。
  • MRI评分≥3时,PI-RADS与Likert两系统的所有癌检出率为78%、ISUP GG≥2癌检出率为63%。
  • MRI评分≥4时,PI-RADS与Likert两系统的所有癌检出率为75%、ISUP GG≥2癌检出率为61%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To audit diagnostic yields of the updated magnetic resonance imaging (MRI)-directed prostate cancer diagnostic service according to Prostate Imaging - Reporting and Data System (PI-RADS) version 2 and Likert assessments, comparing outcomes of the two scoring systems.

MATERIALS AND METHODS: Consecutive men with suspected cancer undergoing prostate MRI were included. Biopsy rates and histological diagnostic yields of all and International Society of Urological Pathology Grade Group (ISUP GG) ≥2 cancers according to PI-RADS and Likert assessment categories were documented and outcomes compared.

RESULTS: Of 326 men (91% biopsy naive), 177 (54%) underwent transrectal (n=119) or transperineal (n=58) ultrasound-guided biopsies; 92% with negative MRI avoided immediate biopsies following multidisciplinary team (MDT) review. All cancer and ISUP GG ≥ 2 cancer-detection rates increased with increasing suspicion scores. Prospective paired PI-RADS and Likert scoring was undertaken in 323/326 studies, with 87% concordance rate. High concordance between PI-RADS and Likert scores was observed in negative MRI (99%) and score 5 (96%). High discordance was demonstrated in the PI-RADS 4 group (32% with PI-RADS 4 categories up-risked to Likert 5). All cancer and ISUP GG ≥ 2 cancer detection rates for MRI score ≥3 were 78% and 63%, and for MRI score ≥4 were 75% and 61%, respectively for both PI-RADS and Likert scoring systems.

CONCLUSIONS: Most men with negative prostate MRI can avoid immediate biopsies following MDT review. Performance of PI-RADS and Likert scoring systems in clinically significant cancer detection after positive MRI is equivalent. Discordance between PI-RADS and Likert systems seems mostly confined to PI-RADS 4 categories.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Sokhi, Wilson, Pindoria, et al. Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems. Clin Radiol. 2022. PMID: 35570157. doi:10.1016/j.crad.2022.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。